Informação sobre produto
Nome:APD 668
Marca:Biosynth
Descrição:APD 668 is an amide-based drug that has been shown to have clinical benefits in chronic treatment of type 2 diabetes. It has been shown to activate the glucagon-like peptide-1 receptor (GLP-1R) and increase the release of insulin. APD 668 decreases hepatic steatosis, insulin resistance, and inflammatory diseases associated with diabetes. APD 668 possesses pharmacokinetic properties that make it suitable for long-term treatment of type 2 diabetes. The drug is metabolized by esterases in plasma and tissues to form a fatty acid metabolite, which can be detected in plasma and urine. The drug also contains a hydroxyl group on the amide side chain that can react with benzyl groups in vivo to form a benzyloxycarbonyl derivative. This derivative is excreted into urine as a conjugate or as free metabolites.
APD 668 increases glucose levels but does not increase blood pressure.
APD 668 increases glucose levels but does not increase blood pressure.
Aviso:Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Propriedades químicas
Peso molecular:477.51 g/mol
Fórmula:C21H24FN5O5S
Pureza:Min. 95%